These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227 [TBL] [Abstract][Full Text] [Related]
10. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. Evin G; Zhu A; Holsinger RM; Masters CL; Li QX J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315 [TBL] [Abstract][Full Text] [Related]
11. Secretase inhibitors and modulators for Alzheimer's disease treatment. Tomita T Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777 [TBL] [Abstract][Full Text] [Related]
12. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. Hook VY; Reisine TD J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316 [TBL] [Abstract][Full Text] [Related]
13. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. Marcade M; Bourdin J; Loiseau N; Peillon H; Rayer A; Drouin D; Schweighoffer F; Désiré L J Neurochem; 2008 Jul; 106(1):392-404. PubMed ID: 18397369 [TBL] [Abstract][Full Text] [Related]
14. Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides. Houacine J; Bolmont T; Aeschbach L; Oulad-Abdelghani M; Fraering PC Neurobiol Aging; 2012 Nov; 33(11):2704-14. PubMed ID: 22317957 [TBL] [Abstract][Full Text] [Related]
15. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. Gasparini L; Ongini E; Wenk G J Neurochem; 2004 Nov; 91(3):521-36. PubMed ID: 15485484 [TBL] [Abstract][Full Text] [Related]
16. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Refolo LM; Pappolla MA; LaFrancois J; Malester B; Schmidt SD; Thomas-Bryant T; Tint GS; Wang R; Mercken M; Petanceska SS; Duff KE Neurobiol Dis; 2001 Oct; 8(5):890-9. PubMed ID: 11592856 [TBL] [Abstract][Full Text] [Related]
17. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629 [TBL] [Abstract][Full Text] [Related]
18. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400 [TBL] [Abstract][Full Text] [Related]
19. Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently. Fu H; Dou J; Li W; Cui W; Mak S; Hu Q; Luo J; Lam CS; Pang Y; Youdim MB; Han Y Eur J Pharmacol; 2009 Nov; 623(1-3):14-21. PubMed ID: 19765582 [TBL] [Abstract][Full Text] [Related]
20. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]